



Classification of Focus
● Active foci

I. Epidemiological profile


Population (UN)	2016	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	24,000	4	Plasmodium species: <i>P. falciparum</i> (9%), <i>P. vivax</i> (91%)
Low transmission (0-1 cases per 1000 population)	59,000	11	Major anopheles species: <i>An. darlingi</i> , <i>An. nuneztovari</i>
Malaria-free (0 cases)	476,000	85	Reported confirmed cases (health facility): 76 Estimated cases: ≤ 100
Total	558,400		Confirmed cases at community level: - Reported deaths: 0 Estimated deaths: 0

II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	2006	First-line treatment of unconfirmed malaria	-	-					
	ITNs/ LLINs distributed to all age groups	No	2006	First-line treatment of <i>P. falciparum</i>	AL+PQ(1d)	2004					
IRS	IRS is recommended	No	2006	Treatment failure of <i>P. falciparum</i>	AS+MQ	2004					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	AS	-					
Larval control	Use of larval control recommended	No	-	Treatment of <i>P. vivax</i>	CQ+PQ(14d)	2004					
IPT	IPT used to prevent malaria during pregnancy	N/A	-	Dosage of Primaquine for radical treatment of <i>P. vivax</i>	0.25 mg/Kg (14 days)						
Diagnosis	Patients of all ages should receive diagnostic test	Yes	1955	Type of RDT used	-	-					
	Malaria diagnosis is free of charge in the public sector	Yes	1955								
Treatment	ACT is free of charge for all ages in public sector	Yes	2004	Therapeutic efficacy tests (clinical and parasitological failure, %)							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-	Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	2004	AL	2011-2011	9	9	9	28 days	1	<i>P. falciparum</i>
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	2004	AS+MQ	2013-2014	0	0	0	28 days	1	<i>P. falciparum</i>
	G6PD test is a requirement before treatment with primaquine	No	-	Insecticide resistance tests (mosquito mortality, %)							
	Directly observed treatment with primaquine is undertaken	No	-	Insecticide class	Years	Min	Mean	Max	No. of sites	Species	
System for monitoring adverse reactions to antimalarials exists	-	-	Organophosphates	2013-2013	0.9	0.9	1	2	<i>An. aquasalis</i>		
Surveillance	ACD for case investigation (reactive)	Yes	2000								
	ACD of febrile cases at community level (pro-active)	Yes	2000								
	Mass screening is undertaken	Yes	2000								
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-								
	Foci and case investigation undertaken	-	-								
	Case reporting from private sector is mandatory	Yes	-								

III. Financing


Sources of financing




Government expenditure by intervention in 2016

IV. Coverage

Coverage of ITN and IRS




Cases tested and treated in public sector




V. Impact


Cases treated



Test positivity



Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths

